TY - JOUR
T1 - Diagnostic accuracy of self-reported age-related macular degeneration in the ASPREE Longitudinal Study of Older Persons
AU - McGuinness, Myra B.
AU - Robman, Liubov
AU - Hodgson, Lauren A.B.
AU - Tran, Cammie
AU - Woods, Robyn L.
AU - Owen, Alice J.
AU - McNeil, John J.
AU - Makeyeva, Galina
AU - Abhayaratna, Walter P.
AU - Guymer, Robyn H.
N1 - Funding Information:
The ASPREE study has been supported by the National Health and Medical Research Council, Australia (NHMRC) [334047, 1127060], the National Institutes of Health (NIH) through the National Institute on Aging [UO1AG029824, U19AG062682], the Victorian Cancer Agency (Victorian Government, Australia), and Monash University. A. G. Bayer provided aspirin and matching placebo but played no other part in the trial. The ALSOP sub-study was supported by Monash University, ANZ Trustees, the Wicking Trust and the Mason Foundation. The ASPREE-AMD sub-study was supported by the National Health and Medical Research Council of Australia (research grant 1051625 and equipment grant) and the National Eye Institute at the National Institutes of Health (grant R01EY026890), the Phyllis Connor Memorial Trust, Jack Brockhoff Foundation and Eric Ormond Baker Charitable Trust. CERA provided retinal cameras; Monash University funded two Bio bus clinical vehicles for mobile retinal photography units. CERA receives Operational Infrastructure Support from the Victorian Government. RHG and JJM are supported by the NHMRC Research Fellowship grants (1103013 and 1173690, respectively). The ENVISion and SNORE-ASA retinal imaging sub-studies were supported by the NHMRC (471460 and 1028368, respectively). The funders had no role in study design, data collection, decision to publish or preparation of this manuscript. Open Access funding enabled and organized by CAUL and its Member Institutions.
Publisher Copyright:
© 2023, The Author(s).
PY - 2024/3
Y1 - 2024/3
N2 - Background: The validity of findings from epidemiological studies using self-report of ophthalmic conditions depends on several factors. We assessed the diagnostic accuracy of self-reported age-related macular degeneration (AMD) among older Australians enroled in a primary prevention clinical trial and compared diagnostic accuracy between demographic subgroups. Methods: At baseline (2010–2015), Australian sub-study participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial, underwent bilateral two-field, 45° non-mydriatic colour retinal photography. Beckman classification of any-stage AMD was used as the reference standard diagnosis. Participants were asked whether a doctor had ever diagnosed them with “macular degeneration” (the index test) via a paper-based questionnaire as part of the ASPREE Longitudinal Study of Older Persons (ALSOP) within the first year of enrolment. Results: In total, 4193 participants were included (aged 70–92 years, 50.8% female). Of those, 262 (6.3%) reported having AMD and 92 (2.2%) were unsure. Retinal grading detected 2592 (61.8%) with no AMD, 867 (20.7%) with early, 686 (16.4%) with intermediate and 48 (1.1%) with late AMD (n = 1601 with any-stage AMD, 38.2%). Self-reported AMD had 11.4% sensitivity (95% CI 9.9–13.1) and 96.9% specificity (95% CI 96.2–97.6) for any-stage AMD, with 69.8% and 63.9% positive and negative predictive values. Sensitivity was higher among participants with late-stage AMD (87.5%), older participants (26.8%), and those with poorer vision (41.0%). Conclusions: Although most participants with late-stage AMD were aware of having AMD, the majority with early and intermediate AMD were not. Therefore, findings from studies that rely on disease self-report should be interpreted with caution.
AB - Background: The validity of findings from epidemiological studies using self-report of ophthalmic conditions depends on several factors. We assessed the diagnostic accuracy of self-reported age-related macular degeneration (AMD) among older Australians enroled in a primary prevention clinical trial and compared diagnostic accuracy between demographic subgroups. Methods: At baseline (2010–2015), Australian sub-study participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial, underwent bilateral two-field, 45° non-mydriatic colour retinal photography. Beckman classification of any-stage AMD was used as the reference standard diagnosis. Participants were asked whether a doctor had ever diagnosed them with “macular degeneration” (the index test) via a paper-based questionnaire as part of the ASPREE Longitudinal Study of Older Persons (ALSOP) within the first year of enrolment. Results: In total, 4193 participants were included (aged 70–92 years, 50.8% female). Of those, 262 (6.3%) reported having AMD and 92 (2.2%) were unsure. Retinal grading detected 2592 (61.8%) with no AMD, 867 (20.7%) with early, 686 (16.4%) with intermediate and 48 (1.1%) with late AMD (n = 1601 with any-stage AMD, 38.2%). Self-reported AMD had 11.4% sensitivity (95% CI 9.9–13.1) and 96.9% specificity (95% CI 96.2–97.6) for any-stage AMD, with 69.8% and 63.9% positive and negative predictive values. Sensitivity was higher among participants with late-stage AMD (87.5%), older participants (26.8%), and those with poorer vision (41.0%). Conclusions: Although most participants with late-stage AMD were aware of having AMD, the majority with early and intermediate AMD were not. Therefore, findings from studies that rely on disease self-report should be interpreted with caution.
UR - http://www.scopus.com/inward/record.url?scp=85171655626&partnerID=8YFLogxK
U2 - 10.1038/s41433-023-02754-y
DO - 10.1038/s41433-023-02754-y
M3 - Article
C2 - 37731049
AN - SCOPUS:85171655626
SN - 0950-222X
VL - 38
SP - 698
EP - 706
JO - Eye
JF - Eye
IS - 4
ER -